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ABSTRACT
PTPRJ is a receptor protein tyrosine phosphatase with tumor suppressor activity. 
Very little is known about the role of PTPRJ ectodomain, although recently both 
physiological and synthetic PTPRJ ligands have been identified. A putative shorter 
spliced variant, coding for a 539 aa protein corresponding to the extracellular 
N-terminus of PTPRJ, is reported in several databases but, currently, no further 
information is available.
Here, we confirmed that the PTPRJ short isoform (named sPTPRJ) is a soluble 
protein secreted into the supernatant of both endothelial and tumor cells. Like PTPRJ, 
also sPTPRJ undergoes post-translational modifications such as glycosylation, as 
assessed by sPTPRJ immunoprecipitation. To characterize its functional activity, we 
performed an endothelial cell tube formation assay and a wound healing assay on 
HUVEC cells overexpressing sPTPRJ and we found that sPTPRJ has a proangiogenic 
activity. We also showed that sPTPRJ expression down-regulates endothelial adhesion 
molecules, that is a hallmark of proangiogenic activity. Moreover, sPTPRJ mRNA levels 
in human high-grade glioma, one of the most angiogenic tumors, are higher in tumor 
samples compared to controls. Further studies will be helpful not only to clarify the 
way sPTPRJ works but also to supply clues to circumvent its activity in cancer therapy.
INTRODUCTION
The molecular signaling of the Protein Tyrosine 
Phosphatase Receptor J (PTPRJ) is implicated in a wide 
variety of physiological and pathological processes, and 
the level of this protein is important for modulation of 
the activity of various tyrosine kinase receptors [1–6]. 
While PTPRJ extracellular region, formed by nine 
fibronectin-like domains, is crucial for the binding of 
ligands, as Syndecan-2 and Thrombospondin-1 [7, 8], 
its intracellular region is composed of a single catalytic 
domain [9]. PTPRJ expression is decreased in many 
cancer cells [10, 11] and its restoration is able to suppress 
the malignant phenotype [12–14]. PTPRJ also shows a 
significant role in angiogenesis, since in endothelial cells, 
the dephosphorylation of Vascular Endothelial Growth 
Factor Receptor-2 (VEGFR-2) mediated by PTPRJ results 
in the inhibition of the Vascular Endothelial Growth Factor 
(VEGF)-induced mitogenic signals [5, 15, 16].
Besides the classical receptor-type phosphatase, 
PTPRJ encodes for an alternative spliced variant 
(NM_001098503.1 - NCBI Gene database) that includes 
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the first eight exons of PTPRJ and an alternative exon 
nine with a stop-codon. The putative 539 aa protein coded 
by the small transcript is formed by the first five type III 
fibronectin domains of the extracellular region of PTPRJ 
and for this reason, it is predicted to be secreted by the 
cells. So far, no experimental evidence of the expression 
and function of the short form of PTPRJ (named sPTPRJ 
from herein) are reported.
Alternative splicing of messenger RNA during 
the maturation of pre-mRNA is an important post-
transcriptional regulation mechanism in eukaryotic cells. 
A large number of genes in eukaryotes are alternatively 
spliced into several forms. In this way, multiple proteins 
with different functions can be produced from a single 
gene [17, 18]. Many soluble receptors are produced by 
alternative splicing, being the translation of receptor 
mRNA prematurely terminated and producing receptors 
that lack the transmembrane and cytoplasmic domains 
[19–22]. Protein-tyrosine phosphatases (PTPs) with 
different forms generated by alternative splicing that 
have equal, contrasting or different functions have been 
already described. Sakurai T. et al. identified proteins 
corresponding to three splicing variants of the protein 
tyrosine phosphatase RPTP beta. Two of these forms are 
receptors that differ in a large extracellular domain, the 
third one is a secreted proteoglycan called phosphacan 
and lacks the cytoplasmic phosphatase domains [23, 
24]. In rodents, four different isoforms of PTPRG, a 
transmembrane protein that behaves as a tumor suppressor, 
are derived from alternative splicing. One of these, 
PTPRG-S, is shown to be an extracellular variant secreted 
into culture medium when expressed in COS7 cells and, 
recently, Moratti et al. have shown its expression in human 
and murine plasma and tissues [25–28].
In this study, for the first time, we identified 
and characterized sPTPRJ. We show that sPTPRJ is a 
glycosylated protein expressed in many cell lines and 
secreted into cell culture medium. It is able to promote 
angiogenesis and cell migration. Moreover, sPTPRJ 
mRNA levels are upregulated in high-grade glioma, a 
tumor in which elevated angiogenesis plays a fundamental 
role to confer high-grade malignancy and poor prognosis 
[29–33].
RESULTS
sPTPRJ protein is endogenously expressed in 
various cell lines
As previously described, the alternative splicing 
of PTPRJ mRNA provides a 3193bp transcript, named 
sPTPRJ, much smaller than PTPRJ transcript formed 
by 7854 bp. These transcripts differ in their 3′UTR 
(untranslated region) sequences; in particular, PTPRJ 
untranslated region has been well studied by Paduano 
et al. [34]; conversely sPTPRJ 3’UTR has not yet 
been studied. The 539 aa sPTPRJ protein is formed by 
five type III fibronectin domains whereas the 1337 aa 
PTPRJ protein is formed by nine type III fibronectin 
extracellular domains, a short transmembrane region 
and a catalytic cytoplasmic domain [9]. Transcripts (top 
panel) and proteins (bottom panel) are represented in 
Figure 1A.
First, the entire coding sequence of sPTPRJ was 
cloned into the pcDNA3.1 vector as described in Material 
and Methods. The expected molecular weight of sPTPRJ 
is approximately 60 kDa. However, two protein bands 
of approximately 100 kDa and 60 kDa were identified 
by Western blot in transfected HEK293 cells (Figure 
1B). In order to understand which form of sPTPRJ was 
expressed in various cell lines, we performed a Western 
blot analysis. Most of the cell lines expressed only the 
60 kDa form, whereas others (i.e., HeLa cells) expressed 
both forms. sPTPRJ was expressed either in adherent or 
suspension cell cultures (i.e., KASUMI cells), as well as in 
tumor and normal (i.e., HUVEC, Human Umbilical Vein 
Endothelial Cells) cell lines (Figure 1C). These results 
suggest that sPTPRJ, in a similar manner to PTPRJ [35], 
is an ubiquitously expressed protein.
sPTPRJ is a soluble protein secreted in 
extracellular compartment
Since sPTPRJ does not possess a transmembrane 
domain, it should have an extracellular localization. To 
confirm this hypothesis, immunoprecipitation of sPTPRJ 
was performed from the culture medium of HeLa, HUVEC 
and A549 cells that possess different levels and forms of 
sPTPRJ (Figure 1D). Cell culture medium of sPTPRJ/
pcDNA3.1 transfected HEK293 cells was used as positive 
control. Interestingly, only the 100 kDa form of sPTPRJ 
was immunoprecipitated from the culture medium of 
cell lines. The 60 kDa detected in the cell lysates (Figure 
1C) did not immunoprecipitate from the culture medium. 
These data could mean that the sPTPRJ form with higher 
molecular weight is the only secreted form. However, 
since in some cell lines, the 100 kDa band observed in the 
immunoprecipitates from the medium is not detectable in 
cell lysates, the possibility of an unspecific precipitation 
of a 100 kDa protein could not be totally discarded. 
Alternatively, in some cell lines, the 100 kDa form of 
sPTPRJ could be synthesized and then rapidly secreted 
in the medium.
In some cell lines, expression of PTPRJ is 
increased in confluent cells in comparison to sparse cells 
[35]. To find if this happens also in the case of sPTPRJ, 
HeLa and ADF cells were grown and total RNA were 
then extracted from sparse (approximately 50 percent 
confluency) and confluent cells. In both cell lines the 
expression of PTPRJ increased in confluent cells, 
whereas no change was detected in sPTPRJ mRNA 
levels (Supplementary figure).
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sPTPRJ is endogenously N-glycosylated
The analysis of the protein sequence of sPTPRJ 
has identified twenty putative N-glycosylation sites 
(Uniprot database). On this basis, we hypothesized 
that the glycosylation state of the protein might be 
responsible for the two different molecular weight bands 
identified by Western blot (Figures 1B-1C). For this 
reason, HEK293 cells were transfected with sPTPRJ/
pcDNA3.1 and then treated with Tunicamycin, a potent 
inhibitor of eukaryote N-acetylglucosamine transferases. 
Cells and culture media were collected and Western 
blot of lysates and immunoprecipitation from cell 
culture media were performed. Western blot of sPTPRJ 
in lysates of tunicamycin-treated cells revealed that the 
intensity of protein band of 60 kDa increased whereas 
the intensity of the 100 kDa sPTPRJ form decreased 
significantly in comparison with the control sample (Left 
Figure 1: sPTPRJ is an endogenously expressed protein with extracellular localization and different glycosylation 
states. A. The upper panel shows the two mRNA variants produced by alternative 9a/b exons; the spliced (3193bp) and the full length 
(7854bp) forms of PTPRJ. The bottom panel represents the structure of the relative codified proteins. In particular, the 539 aa sPTPRJ 
protein is composed of 5 type III fibronectin domains, instead of the 1337 aa PTPRJ protein is formed by 9 type III fibronectin extracellular 
domains, a transmembrane and a single catalytic cytoplasmic domain. B. The spliced mRNA variant codify for the sPTPRJ protein; 
HEK293 cells were transfected with pcDNA3.1 vector, empty or carrying sPTPRJ-WT/H6. Cell lysates were subjected to immunoblots 
using an anti-PTPRJ antibody specific for the extracellular portion of the protein. Two protein bands with different molecular weight are 
detectable, one at about 60 kDa and the other at about 100 kDa. Anti-GAPDH antibody was used to check equal loading. C. sPTPRJ is 
endogenously expressed in several normal and cancer cell lines. A549, HUVEC, MCF7, HeLa, A172 and ADF cell lysates were subjected 
to immunoblots using an anti-PTPRJ antibody specific for the extracellular portion of the protein. All cell lines express the 60 kDa protein, 
others, as HeLa cells, the 60 kDa and the 100 kDa forms. Lysate of HEK293 cells transfected with sPTPRJ/pcDNA3.1 was used as positive 
control. D. sPTPRJ is secreted in the extracellular compartment. Immunoprecipitation of sPTPRJ from cell culture media of HeLa, A549 
and HUVEC cells was performed. Detection was carried out using an anti-PTPRJ antibody. Cell culture medium of sPTPRJ/pcDNA3.1 
transfected HEK293 cells was used as positive control. E. sPTPRJ possesses different glycosylation states. HEK293 cells transfected with 
sPTPRJ/pcDNA3.1 were treated with 5 μg/ml Tunicamycin or DMSO as negative control. In the left panel, cell lysates were subjected to 
immunoblots using an anti-PTPRJ antibody specific for the extracellular portion of the protein. Anti-GAPDH antibody was used to check 
equal loading. In the right panel, immunoprecipitation of sPTPRJ from cell culture media was performed. Detection was carried out using 
an anti-PTPRJ antibody.
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panel Figure 1E). Moreover, immunoprecipitation from 
cell culture media showed that both forms of sPTPRJ 
could be secreted, indicating that N-glycosylation is not 
indispensable for protein secretion, but it could be needed 
to regulate the maturation of the protein (Right panel 
Figure 1E).
sPTPRJ expression does not influence cell 
proliferation
PTPRJ agonist peptides, identified by Paduano et 
al., are able to bind and activate PTPRJ in its extracellular 
portion and to reduce proliferation of cancer cells [36, 
37]. In order to understand if sPTPRJ expression can 
directly influence proliferation and if it could be a soluble 
protein able to bind membrane receptors and influence 
cell proliferation, we analyzed the cell proliferation of 
HUVEC cells and glioblastoma ADF and A172 cell lines 
infected with Ad5-GFP, Ad5-sPTPRJ (generation and 
testing of sPTPRJ recombinant adenovirus are reported in 
Materials and Methods) or Ad5-PTPRJ [36]. In agreement 
with the anti-proliferative effect of the rat PTPRJ observed 
in glioblastoma cell lines [38], the proliferation rate of 
Ad5-PTPRJ infected cells was reduced compared to 
Ad5-GFP infected cells; however, there was no change 
in the proliferation of cells overexpressing sPTPRJ (Ad5-
sPTPRJ, Figure 2).
sPTPRJ expression in HUVECs activates 
angiogenesis and cell migration
Several studies reported the importance of PTPRJ 
in angiogenesis [16, 37, 39–43]. To establish if sPTPRJ is 
involved in angiogenesis, we carried out two different in 
vitro assays using endothelial cells.
HUVECs were infected with Ad5-GFP or Ad5-
sPTPRJ and then seeded on a polymerized Matrigel layer, 
in the presence of VEGF. Kinetics of tube formation of 
endothelial cells were recorded as a proof of the initial 
step of neo-angiogenesis. Results showed that cells 
infected with the adenovirus expressing sPTPRJ are able 
to form tubes nearly three times more than control cells. 
To further investigate the role of sPTPRJ, we also treated 
cells with PTPRJ-19.4, a specific PTPRJ agonist peptide. 
In agreement with our recent published findings, the 
treatment of HUVEC cells with the PTPRJ agonist peptide 
[37] resulted in a reduction of new vessel formation 
(Figure 3A).
To further confirm the involvement of sPTPRJ in 
the endothelial cell migration, we performed a wound-
healing assay. HUVEC cells were infected with empty 
adenovirus or adenovirus carrying sPTPRJ, and after 
24h the cells were scratched. Photographs show that cells 
overexpressing sPTPRJ were able to completely close the 
wound in a time lower than 24h, whereas control cells did 
not (Figure 3B).
sPTPRJ downregulates the expression of the 
endothelial adhesion molecules
Angiogenic factors, such as bFGF (beta-fibroblast 
growth factor) and VEGF, are responsible for down-
regulation of expression of the endothelial adhesion 
molecules ICAM-1 [44] and VCAM-1 [45]. To 
substantiate the potential role of sPTPRJ as an angiogenic 
factor, we analyzed the mRNA expression levels of 
I-CAM and V-CAM in sPTPRJ/pcDNA3.1 transfected 
HEK293 or Ad5-sPTPRJ infected HUVEC cells. Results 
showed that I-CAM and V-CAM mRNA levels decreased 
significantly compared with respective controls (Figure 
4). Interestingly, the down-regulation of the adhesion 
molecules was not due to an increase of VEGF expression. 
The same experiment was carried out overexpressing 
PTPRJ, and in that case I-CAM and V-CAM mRNA levels 
increased significantly in infected HUVECs (Figure 4, 
lower panel).
Figure 2: Cell proliferation is not influenced by sPTPRJ protein expression. To analyze cell proliferation, the Alamar Blue 
assay was performed. Primary endothelial HUVEC, glioblastoma A172 and ADF cells (2.5x103/well) were seeded in a 96-well plate. After 
24h cells were infected with Ad5-PTPRJ or Ad5-sPTPRJ viruses; Ad5-GFP infection was used as control. The same day, Alamar Blue stock 
solution was added. Absorbance at wavelengths 570 nm and 600 nm was determined after 0, 24, 48, 72 and 96h of Alamar Blue incubation. 
The experiment was performed in octuplicate and data are represented as mean ± SD.
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sPTPRJ mRNA levels are elevated in high-grade 
glioma samples
Glioblastoma, the highest grade of glioma, is 
a highly vascularized brain tumor and for its growth 
critically depends on the generation of tumor-associated 
blood vessels.
In glioblastoma, high levels of vasculature have 
been reported to correlate with high-grade malignancy and 
poor prognosis [30]. To understand if sPTPRJ expression 
is changed in high-grade glioma tumor samples, we 
analyzed the mRNA expression levels of sPTPRJ in seven 
non-tumorigenic brain and fourteen high-grade glioma 
samples (four of grade III and ten of grade IV). Results 
showed significantly higher levels (sevenfold increase) 
of sPTPRJ mRNA in the glioma samples compared with 
controls (Figure 5).
DISCUSSION
In this study, for the first time, we characterized 
the short variant of the receptor protein phosphatase 
PTPRJ generated by an alternative splicing. This protein, 
named sPTPRJ, contains only a portion of the N-terminal 
extracellular region of PTPRJ including the signal 
peptide, and for this reason it might be secreted into the 
extracellular space.
The identification of sPTPRJ cell 
compartmentalization is a first key step to understanding 
Figure 3: sPTPRJ protein increases tube formation and cell migration. A. The angiogenic potential of sPTPRJ was determined 
by an endothelial cell tube formation assay performed on HUVEC cells infected with Ad5-sPTPRJ or Ad5-GFP as control. Cells (2.5×104/
well) were plated on Matrigel and treated with VEGF and/or PTPRJ agonist peptide Pep19.4, as molecule able to inhibit tube formation. 
After 24h of incubation, capillary tube formation in each group was photographed using a light microscope. Representative photographs of 
tube formation or degeneration activity induced respectively by sPTPRJ or Pep19.4 and histograms with relative percentage are shown in 
the left panel. In the right panel, Western blot of the sPTPRJ expression was shown. Anti-GAPDH antibody was used to check equal loading. 
Results represent the mean ± SD of three independent experiments. One-way ANOVA followed by Bonferroni’s multiple comparison test 
was used and P value was presented ≤ 0.001 =***. Scale bar = 100 μm. B. Wound healing assay was performed on HUVEC cells infected 
with Ad5-sPTPRJ or Ad5-GFP used as control. In the left panel, photographs show that cells overexpressing sPTPRJ, unlike control cells, 
are able to completely close the wound 24h after cells were scratched. In the right panel, cell migration is expressed as the percentage 
relative to 0h wound width. Data are presented as mean ± SD of three independent experiments and two-tailed Student’s t-test was used. P 
values are presented as ≤ 0.01 =**. Scale bar = 200 μm.
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Figure 4: sPTPRJ overexpression affects I-CAM and V-CAM mRNA levels. Real-time PCR analysis of I-CAM, V-CAM and 
VEGF-A was performed in sPTPRJ or PTPRJ transfected HEK293 (upper panel) and Ad5-sPTPRJ or Ad5-PTPRJ infected HUVEC cells 
(lower panel). PTPRJ and sPTPRJ overexpression were confirmed by real-time PCR (right panels). Values are plotted as fold change or 
Log10 fold change ± SD. One-way ANOVA followed by Bonferroni’s multiple comparison test was used and P values are presented as ≤ 
0.01 =**, ≤ 0.001 =***.
Figure 5: Increased mRNA levels of sPTPRJ in a high-grade glioma cohort. Real-time PCR analysis of sPTPRJ was performed 
on brain tissue samples of non-tumorigenic [n=7] or high-grade glioma [n=14] subjects. Values were normalized to HPRT mRNA levels, 
represented as Log10 fold expression and plotted as geometric mean ± CI 95%. Mann-Whitney U-test was used.
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the possible mechanism of action. By experiments of 
immunoprecipitation and Western blot, we demonstrated that 
overexpressed sPTPRJ is secreted in the culture medium.
By Western blot, we detected two different protein 
isoforms corresponding to sPTPRJ and we showed that 
the diversity of molecular weight is due to changes in 
glycosylation, a post-translation modification that also 
occurs in the large form of PTPRJ [46].
Glycosylation is one of the most common protein 
post-translational modification. N-glycans can modulate 
several cancer cell mechanisms such as metabolism, 
signaling, growth, cell-cell adhesion, cell-matrix 
interaction, migration, invasion and metastasis [47]. Most 
secreted proteins, produced by alternative splicing, can be 
post-translationally glycosylated. For example, RPTPζ/
phosphacan, the soluble spliced variant form of RPTP 
beta, is an important substrate for protein O-mannosylation 
in the brain [48].
Glycosylation of proteins could be important in 
the maturation and positioning of proteins [49]. In native 
conditions cell lines preferentially secreted the fully 
glycosylated sPTPRJ, but the treatment of transfected cells 
with tunicamycin does not block sPTPRJ secretion. Thus, 
N-glycosylation does not seem to affect the secretion of 
sPTPRJ but similarly to what occurs for other secreted 
proteins, it may be relevant to increase the protein stability 
[50–52].
Unlike PTPRJ, the expression of sPTPRJ did not 
show a density-dependent regulation. Since the two 
PTPRJ messenger RNAs share the same promoter but 
have different 3' untranslated regions, the mechanism of 
density-dependent regulation, already observed for PTPRJ 
[35], could be connected to the 3' untranslated region.
Since PTPRJ is involved in angiogenesis [5, 16, 37, 
39–43], to investigate a possible functional role of sPTPRJ 
in this process, endothelial cell tube formation assay and 
wound healing assay were performed using HUVECs. 
Expression of sPTPRJ increases tube formation and 
endothelial cell migration, bringing evidence on its role as 
a bona-fide angiogenic factor.
Angiogenic factors, such as VEGF and bFGF, cause 
a down-regulation of endothelial adhesion molecules, such 
as ICAM-1 [44] and VCAM-1 [45], which is a hallmark 
of pro-angiogenic activity. Forced expression of sPTPRJ 
in HEK293 and HUVEC cells showed that I-CAM and 
V-CAM mRNA levels decreased significantly in both cell 
lines, differently VEGF-A mRNA levels did not change 
in HEK293 and significantly decreased in infected 
HUVECs. These data then support the role of sPTPRJ as 
an angiogenic factor. How to sPTPRJ can generate new 
vessels remains to be defined, but its effect seems to be 
not related to cell growth since its overexpression does 
not influence cell proliferation. Interestingly, in HUVECs 
a dramatic increase of I-CAM and V-CAM mRNA levels 
was detected after overexpression of PTPRJ. These results 
warrant the study of PTPRJ gene in endothelial response 
to inflammation.
Although the relevance of PTPRJ in normal blood 
circulation is clear [39], mechanisms that are involved 
in this process are not completely understood. In 
different studies, activation of PTPRJ resulted to inhibit 
angiogenesis through down-regulation of ERK activity 
[37, 40, 41] or enhance angiogenesis via SRC activation 
[16, 42, 43]. PTPRJ expression levels and different 
experimental models could justify these discrepancies, but 
the role of sPTPRJ has never been studied. Thus, sPTPRJ 
could be a new important player to take in consideration, 
able to influence pro-angiogenic or anti-angiogenic 
pathways regulated by PTPRJ.
The sPTPRJ protein might be a ligand for a 
transmembrane receptor or a decoy ligand for soluble 
proteins; it could then act on other proteins as a positive 
or negative regulator, operating on different interacting 
molecules.
For example, PTPRJ interacts with 
thrombospondin-1 [8] which is a pro-angiogenic protein 
[52] and the binding of PTPRJ to TSP-1 increases the 
catalytic activity of PTPRJ, which is also relevant in the 
angiogenesis inhibition. Moreover, the interaction between 
PTPRJ and TSP-1 occurs in the type 1 repeats of TSP-1, a 
fundamental protein region for the angiogenic role of TSP-
1 [53]. Thus, sPTPRJ could also bind thrombospondin-1 
interfering with TSP-1 binding to other ligands or 
alternatively could compete with the binding of PTPRJ 
reducing its tyrosine phosphatase catalytic activity.
The tumor vasculature of glioblastoma is 
characterized by a dense network of disorganized 
vessels with increased diameter and thickened basement 
membranes [30, 31]. Targeting angiogenesis has been 
and continues to be an attractive therapeutic modality 
in both newly diagnosed and recurrent glioblastoma 
patients [54]. Thus, glioblastoma is a good tumor model 
to test the possibility that sPTPRJ can contribute to 
tumor angiogenesis in vivo. The expression of sPTPRJ 
is significantly higher in high-grade glioma samples than 
in control brains, supporting that this protein could be 
involved in tumor angiogenesis.
Our data demonstrate that sPTPRJ can be 
considered a bona-fide angiogenic factor, and on the basis 
of these findings sPTPRJ may has a role in the feeding of 
glioblastoma cells by the generation of new tumor vessels. 
Taken together, these data show that sPTPRJ could 
represent a novel candidate biomarker in glioblastoma. 
More studies are needed to identify the interacting 
molecules and pathways involved in the sPTPRJ action 
and to study its expression in other cancer types.
MATERIALS AND METHODS
Cell lines and transfections
A549 lung cancer and ADF human glioblastoma cell 
lines were cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (Sigma-Aldrich) [55]. HeLa 
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cervical cancer, MCF-7 mammary cancer, HEK293 human 
embryonic kidney and A172 human glioblastoma cell 
lines were maintained in DMEM medium supplemented 
with 10% FBS (Sigma-Aldrich). Human endothelial vein 
HUVEC cells were cultured in medium-200 supplemented 
with LSGS (Gibco). All cells were cultured in medium 
with 1% penicillin-streptomycin solution (Invitrogen) at 
37°C in a humidified atmosphere with 5% CO2.
Transfections were performed in HEK293 cells. 
The day before transfection, cells were seeded at a density 
of 3x106 in 60 mm plates. sPTPRJ-WT/H6 and PTPRJ 
in pcDNA3.1 or pcDNA3.1 empty vector plasmids 
were mixed with Lipofectamine 2000 (Invitrogen) 
for 20 minutes at room temperature according to the 
manufacturer’s instructions. The mixtures were then 
applied to the cells in a final volume of Opti-MEM I 
(Invitrogen). After incubation for 8 hours at 37°C, DMEM 
supplemented with serum was added. Cells were then 
cultured for additional 72 hours at 37°C before further 
analysis.
Human samples
Human brain tumor samples were collected from 
the Neurosurgery Unit of the IRCCS-AOU San Martino 
IST (Genova, Italy), after patients’ informed consent 
and Institutional Ethical Committee approval. After the 
surgery, tumor specimens were immediately frozen at 
-80°C till the processing for mRNA extraction. Non-tumor 
brain samples derive from the Brain Bank at Case Western 
Reserve University (Cleveland, OH) and are a kind gift of 
Prof. Claudio Russo (University of Molise, Italy).
Antibodies and Western blot analysis
Mouse monoclonal antibody against PTPRJ 
was purchased from R&D Systems. Rabbit polyclonal 
antibody against PTPRJ was purchased from Abcam. 
These antibodies were generated to recognize PTPRJ 
but they can also be used for sPTPRJ because are raised 
against the extracellular region of PTPRJ spanning from 
the first to the second fibronectin domain. Horseradish 
peroxidase(HRP)-conjugated anti-rabbit and anti-mouse, 
anti-GAPDH antibodies and normal mouse IgG were 
purchased from Santa Cruz Biotechnology.
Cells were lysed in lysis buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM 
Na3VO4, 0.1% aprotinin, 2 mM PMSF and 25 mM 
NaF) and incubated for 30 min on ice. Cellular debris 
were pelleted by centrifugation at 16.000g for 30 min 
at 4°C. Protein concentrations were determined using 
the Bradford protein assay dye (Bio-Rad). Total cell 
lysates were separated by SDS−PAGE and transferred 
to nitrocellulose membranes (Bio-Rad). Membranes 
were blocked in 5% nonfat dry milk (Bio-Rad) and then 
probed for 2 h with primary antibodies. After incubation 
with specific (HRP)-conjugated secondary antibodies, 
protein bands were revealed by the ECL detection system 
(Ge-Healthcare).
Construction of sPTPRJ and sPTPRJ-H6/
pcDNA3.1 vectors
A pBluescript-PTPRJ recombinant vector was 
digested with the Bpu1102I and XbaI restriction 
endonucleases. The 3' region of PTPRJ from the Bpu1102I 
site until the stop codon of PTPRJ was removed and 
substituted with a Bpu1102I/XbaI fragment containing 
the 3' of sPTPRJ. This fragment was generated by PCR 
amplification using Pfu DNA-polymerase, HeLa cDNA as 
template and the following primers: Forward (upstream 
of Bpu1102I site) 5'-GGTCAGCACGACGGAGA-3'; 
Reverse (sPTPRJ) 5'-CCATCTAGATCATCCAGTTCT
ATTGCAAACTGTC-3'; Reverse (sPTPRJ-H6) 5'-CCA 
TCTAGATCAGTGATGGTGATGGTGATGTCCAGTTC 
TATTGCAAACTGTC-3'. The pBluescript-sPTPRJ 
recombinant vectors were then digested with NotI and 
the full-length sPTPRJ were excised and sub-cloned 
into the pcDNA3.1 vector, linearized with the same 
restriction enzyme. Recombinant vectors were checked 
by sequencing.
Immunoprecipitation from cell culture media 
and tunicamycin treatment
Cell culture media (10 ml) of HeLa, HUVEC, 
A549 and sPTPRJ/pcDNA3.1 transfected HEK293 cells 
(positive control) were collected and precleared with 15 μl 
of protein A/G plus-agarose(Santa Cruz Biotechnologies). 
Cell media were then incubated overnight with anti-PTPRJ 
or normal IgG antibodies and protein A/G plus-agarose. 
After five washes in PBS 1X, immunoprecipitated proteins 
were detached from the agarose beads by heat treatment at 
99°C for 5 minutes in 2X loading buffer and then analyzed 
by Western blot.
To characterize the glycosylation state of sPTPRJ, 
HEK293 cells transfected with sPTPRJ/pcDNA3.1 
were treated 24h after the transfection with 5 μg/ml 
Tunicamycin (Sigma-Aldrich) or DMSO (Sigma-Aldrich), 
as negative control. 48h later, cells were collected and 
Western blot of cell lysates and immunoprecipitated 
sPTPRJ from cell culture media was performed.
Generation and validation of recombinant 
adenoviruses carrying a human WT/H6-tagged 
sPTPRJ cDNA
The newly generated sPTPRJ and sPTPRJ-H6 
cDNA were excided from sPTPRJ or sPTPRJ-H6/
pCDNA3.1 with NotI and were cloned in the 
transfer vector pAdenoVator-CMV5(CuO)-IRES-
GFP (Qbiogene) linearized with NotI. Recombinant 
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transfer vectors were linearized with PmeI and then 
electroporated with the construct AdVator ΔE1/E3 
containing the defective adenoviral genome into E. 
coli BJ5183 cells. The resulting vectors were linearized 
with PacI and transfected into HEK293 cells by 
Lipofectamine to package viruses. Single viral plaques 
were isolated, expanded, and checked for sPTPRJ 
or sPTPRJ-H6 expression. Viruses were purified by 
Vivapure AdenoPACK 100 (Vivascience) and titration 
was performed by the TCID50 method.
The adenoviruses carrying sPTPRJ or sPTPRJ-H6 
were validated by infection of A549 cells at a multiplicity 
of infection (MOI) of 25, analysis of Green Fluorescent 
Protein (GFP) by fluorescent microscopy (Leica), 
immunoblots of cell lysates and purification of His6-
tagged protein from cell culture media by poly(His)-avid 
magnetic beads (Promega).
Proliferation assay
The Alamar Blue assay (BioSource Int.) was 
used to measure cell proliferation. The dye used is an 
oxidation-reduction indicator and cellular metabolism 
induces a chemical reduction of the Alamar Blue medium. 
To perform the experiment, cells were infected with 
adenoviruses carrying sPTPRJ or PTPRJ and with an 
empty adenovirus as control. The appropriate MOI for cell 
line was used. Alamar Blue stock solution was aseptically 
added at 1:10 dilution. Absorbance at wavelengths 
570 nm and 600 nm was determined by Multiskan GO 
(Thermo Scientific). Data were obtained following the 
manufacturer’s protocols.
Endothelial cell tube formation assay
Unpolymerized Matrigel (Becton Dickinson) 
diluted 1:2 in nude medium-200 was placed (50 μL/well) 
in a 96-well microtiter plate and polymerized for 1h at 
37°C. HUVEC cells previously infected for 48h with 
adenovirus empty or carrying sPTPRJ at MOI 80, were 
seeded (2.5×104/well) onto the solidified Matrigel in 
complete medium-200 added with VEGF (20 ng/ml) and/ 
or PTPRJ agonist peptide pep19.4 at the concentration 
of 160 μM. After 24h of incubation at 37°C and 5% 
CO2, tube formation was analyzed by light microscopy 
(Leica). Quantification was performed by counting the 
number of tube-like structures in three randomly selected 
microscopic fields.
Scratch assay
HUVEC cells were seeded in a 6-well plate to 
obtain after 72h a confluence of 100%. After 24h plated 
cells were infected at MOI 80 with adenovirus empty 
or carrying sPTPRJ. 48h later cell monolayers were 
scratched with a 0.2 ml pipette tip, washed twice, and 
photographs were taken. The width of wound at 6h 
and 24h was measured using Image J software (http://
rsbweb.nih.gov/ij/). Cell migration was expressed as 
percentage relative to the width measured at the time 
zero.
Quantitative real-time PCR
RNA extraction from PTPRJ/pcDNA3.1, sPTPRJ/
pcDNA3.1 or pcDNA3.1 empty vector transfected 
HEK293 cells and from Ad5-PTPRJ, Ad5-sPTPRJ 
or Ad5-GFP infected HUVEC cells was performed 
with miRNeasy Mini Kit (Qiagen), following the 
manufacturer’s protocol. Total RNA samples (1 μg) were 
subjected to the reaction of reverse-transcription using the 
High Capacity RNA-to-cDNA Kit (Applied Biosystems). 
One microliter of cDNAs was amplified by real-time PCR, 
in a BioRad IQ_5 apparatus, with Promega SYBR green 
kit and 10 pmol of primers in a total volume of 20 μl. 
The primers used to amplify endogenous I-CAM1 mRNA 
were: 5'-ATGCCCAGACATCTGTGTCC-3' (forward), 
5'-GGGGTCTCTATGCCCAACAA-3' (reverse). To 
amplify endogenous V-CAM1 mRNA the primers were: 
5'-GGGAAGATGGTCGTGATCCTT-3' (forward), and 
5'-TCTGGGGTGGTCTCGATTTTA-3' (reverse). To 
amplify endogenous VEGF-A mRNA the primers were: 
5'-CGAGGGCCTGGAGTGTGT-3' (forward), and 
5'-CGCATAATCTGCATGGTGATG-3' (reverse).
RNAs from patients (fourteen high-grade glioma 
samples) and controls (seven non-tumorigenic brain 
samples) were extracted by trizol and reverse-transcribed 
as described above. Quantitative real-time PCR was 
performed to determine sPTPRJ mRNA levels. The primers 
used were: 5'-GTATTATCATTGGTGGCTTGTTC-3' 
(forward) and 5'-AGGCAGGTGTTCAAATCATCC-3' 
(reverse). Specific oligonucleotides used for amplification 
of hypoxanthine phosphoribosyl-transferase (HPRT) 
mRNA (normalization control) were reported by 
Vandesompele et al. [56]. Relative expression levels were 
calculated by the ΔΔCt method.
Statistical methods and data analysis
Experiments were done at least three times, and 
results were expressed as mean ± standard deviation 
(SD). Proliferation assay was performed in octuplicate. 
Real-time PCR, tube formation and wound healing 
assays were performed in triplicate. Differences 
between groups were analyzed using unpaired two-
tailed Student’s t-test or one-way ANOVA followed by 
Bonferroni’s multiple comparison test. To compare non-
tumorigenic and high-grade glioma samples a Mann-
Whitney U-test was used. Statistical analyses were 
performed using a statistics program (GraphPad Prism; 
GraphPad Software, La Jolla, CA, USA). In the figures, 
P value thresholds are represented as: P ≤ 0.05 =*, P ≤ 
0.01 =** and P ≤ 0.001 =***.
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